The Association Between Exposure to Spironolactone or Amiloride and Fracture Risk Among Subjects Treated With Thiazolidinediones.

Trial Profile

The Association Between Exposure to Spironolactone or Amiloride and Fracture Risk Among Subjects Treated With Thiazolidinediones.

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs Amiloride; Pioglitazone; Rosiglitazone; Spironolactone; Troglitazone
  • Indications Fracture; Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 05 Mar 2010 Planned end date changed from 1 May 2011 to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 05 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 03 Feb 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top